PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms

MLA

J. Ávila, et al. “PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-Line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms.” Journal of Thoracic Oncology, vol. 14, Nov. 2019, pp. S1172–73. EBSCOhost, https://doi.org/10.1016/j.jtho.2019.09.133.

APA

J. Ávila, Luis Mas, Feliciano Barrón, L. Corrales-Rodriguez, Helano C. Freitas, C. Martin, Rosa Rosell, C. Sotelo, Pilar Archila, L. Zatarain Barron, Andrés Felipe Cardona, Alejandro Ruiz-Patiño, Carlos Vargas, V. Cordeiro De Lima, Hernán Carranza, Oscar Arrieta, D. Mayorga, July Rodriguez, Jorge Otero, & Luisa Ricaurte. (2019). PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms. Journal of Thoracic Oncology, 14, S1172–S1173. https://doi.org/10.1016/j.jtho.2019.09.133

Chicago

J. Ávila, Luis Mas, Feliciano Barrón, L. Corrales-Rodriguez, Helano C. Freitas, C. Martin, Rosa Rosell, et al. 2019. “PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-Line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms.” Journal of Thoracic Oncology 14 (November): S1172–73. doi:10.1016/j.jtho.2019.09.133.